Table 5.

Summary of ESAS scores and treatment-related outcomes in study patients at baseline and at week 4

Factors	Baseline					Week 4
	Non-neuropathic group (n = 92)	Neuropathic group (n = 41)	Mean difference (95% CI)	P value		Non-neuropathic group (n = 60)	Neuropathic group (n = 23)	Mean difference (95% CI)	P value
ESAS
Pain	5.58 ± 2.93	5.90 ± 2.90	0.326 (–0.758, 1.411)	0.553		3.68 ± 2.98	4.26 ± 3.17	0.578 (–0.901, 2.056)	0.439
Tiredness	2.47 ± 2.70	4.73 ± 3.27	2.264 (1.193, 3.335)	< 0.001		2.60 ± 3.15	2.87 ± 3.02	0.270 (–1.250, 1.789)	0.725
Nausea	1.11 ± 2.15	1.12 ± 2.19	0.013 (–0.790, 0.817)	0.974		1.00 ± 2.08	0.61 ± 1.31	–0.391 (–1.317, 0.534)	0.403
Depression	0.97 ± 1.90	2.20 ± 3.11	1.228 (0.176, 2.279)	0.023		0.72 ± 1.57	0.65 ± 1.92	–0.064 (–0.882, 0.753)	0.876
Anxiety	2.05 ± 2.82	3.51 ± 3.28	1.458 (0.279, 2.637)	0.016		1.18 ± 2.19	1.70 ± 2.32	0.512 (–0.575, 1.599)	0.351
Drowsiness	1.90 ± 2.49	2.98 ± 2.95	1.073 (0.094, 2.053)	0.032		2.35 ± 2.88	2.43 ± 2.69	0.085 (–1.297, 1.466)	0.903
Lack of appetite	3.96 ± 3.23	4.00 ± 3.57	0.043 (–1.196, 1.283)	0.945		2.82 ± 2.93	3.96 ± 3.54	1.140 (–0.376, 2.656)	0.139
Poor well-being	3.45 ± 3.34	4.37 ± 3.31	0.920 (–0.317, 2.157)	0.143		1.90 ± 3.86	2.09 ± 2.95	0.187 (–1.222, 1.596)	0.792
Shortness of breath	1.59 ± 2.68	3.32 ± 3.57	1.730 (0.484, 2.976)	0.007		1.43 ± 2.52	1.91 ± 2.83	0.480 (–0.792, 1.752)	0.455
Symptom distress score	26.52 ± 16.09	35.88 ± 15.75	9.356 (3.417, 15.296)	0.002		20.77 ± 16.79	23.30 ± 14.39	2.538 (–5.353, 10.428)	0.524
Treatment-related outcomes
Patient's satisfaction	4.49 ± 3.38	3.83 ± 3.61	–0.660 (–1.940, 0.621)	0.310		6.98 ± 3.33	6.17 ± 3.79	–0.809 (–2.497, 0.878)	0.343
Drowsiness	33 (35.9)	18 (43.9)		0.379		24 (40.0)	12 (52.2)		0.317
Nausea or vomiting	23 (25.0)	9 (22.0)		0.704		11 (18.3)	3 (13.0)		0.748
Constipation	42 (45.7)	17 (41.5)		0.653		20 (33.3)	12 (52.2)		0.114

Values are presented as mean ± standard deviation or number (%).

ESAS: Edmonton Symptom Assessment Scale, CI: confidence interval.